Tamoxifen

Limits on what this shows

• Key negative/null finding: None found measuring systemic mitochondrial function in tamoxifen-treated humans, positive or negative; this is the evidence gap, not a null result.
• At-risk subgroups: Not established in humans. Mouse hepatic mtDNA depletion was linked to steatosis, which parallels the roughly one-in-three rate of fatty liver seen clinically by five years of tamoxifen therapy, but a causal chain to that clinical finding has not been directly demonstrated.

Population evidence

Mouse liver, in vivo: tamoxifen inhibits topoisomerases, depletes mitochondrial DNA and triggers hepatic steatosis. J Pharmacol Exp Ther. 2007;321(2):526-535. PMID 17277197. Isolated mitochondria, in vitro: tamoxifen blocks reactive-oxygen-species generation and multiple markers of Cu2+-orthophenanthroline-induced mitochondrial permeability transition (matrix calcium release, swelling, membrane-potential collapse, mtDNA disruption), a protective finding against a specific oxidative insult rather than evidence of tamoxifen itself causing that insult. Cell Biol Int. 2016. PMID 27730705.

Mechanism

Direct topoisomerase inhibition and mtDNA depletion at hepatocyte level (mouse); separately, tamoxifen's phenolic/triphenylethylene structure gives it intrinsic radical-scavenging chemistry that can be protective against certain oxidative insults in isolated mitochondria. Both mechanisms are named and drug-specific, not extrapolated from class.

Counter-evidence held on record

No supplement dose is implied or recommended by this entry. This is a mechanism-level, animal/in-vitro finding, not a measured human deficiency of any specific mitochondrial cofactor.

Limits on what this shows

• Key negative/tissue-specific finding: A mouse study of prolonged (3-month), high-dose dietary tamoxifen found the opposite locally: increased hepatic lipid peroxidation (MDA, LPO) alongside iron-driven ferroptosis markers in liver tissue specifically. FASEB J. 2025. PMID 39792062. The two findings are not directly contradictory: one is a systemic/circulating measure at standard clinical dosing, the other a liver-tissue measure at supratherapeutic, prolonged dosing in mice.
• At-risk subgroups: None identified for the protective direction; the mouse hepatic ferroptosis signal suggests dose- and duration-dependent risk of a reversal in liver tissue specifically, not established in humans at approved dosing.

Regulatory status

Not addressed in the FDA label; this is a literature-only finding.

Population evidence

Prospective human study, n=64 postmenopausal women with breast cancer, tamoxifen 10 mg twice daily for 6 months. Malondialdehyde (a lipid-peroxidation marker) decreased significantly; enzymic and non-enzymic antioxidants rose; serum selenium and vitamins A, C and E all increased significantly (P<0.01) in parallel. Cancer. 1994. PMID 8004586.

Mechanism

Tamoxifen and its hydroxylated metabolites are direct peroxyl-radical scavengers and intramembraneous inhibitors of lipid peroxidation in isolated-membrane and nuclear systems; this chemistry plausibly extends to the systemic antioxidant shift seen in patients. Isolated-mitochondria mechanistic literature, see Mitochondrial burden entry.

Counter-evidence held on record

This is a protective, not a depleting, signal. It should never be used to suggest antioxidant supplementation is unnecessary or that oxidative-stress monitoring can be skipped; it should also never be read as license to disregard the separate, tissue-specific hepatic ferroptosis signal seen in animal models of prolonged high-dose exposure.

Population evidence

Rat model, tamoxifen-treated, with serum copper, zinc and manganese as endpoints (confirmed via title, journal, and MeSH indexing: Tamoxifen/adverse effects, Copper/blood). Biol Trace Elem Res. 2016. DOI 10.1007/s12011-016-0629-z. The full abstract text was not retrievable via Crossref, OpenAlex or PubMed during this review; see access note in Sources.

Related mechanistic evidence

In isolated mitochondria, tamoxifen protects against Cu2+-orthophenanthroline-induced oxidative damage (reactive-oxygen-species generation, lipid peroxidation, aconitase inactivation), a protective interaction with copper-catalyzed chemistry rather than evidence about copper nutritional status. Cell Biol Int. 2016. PMID 27730705.

Mechanism

Not established for copper status specifically; the copper-protective mitochondrial chemistry above is a different question (protection against copper-catalyzed oxidative damage) from whether tamoxifen changes copper levels.

Overlap

Shares its source (Cu2+-orthophenanthroline mitochondrial study) with the Mitochondrial burden entry; see Overlap map.

Counter-evidence held on record

This entry is graded yellow on the strength of confirmed Tier B animal evidence existing, not on a confirmed direction of effect. Direction and magnitude are unknown from this review; do not present this as either a depletion or an excess claim until the primary result is verified. This access limitation should be re-checked in any future revision of this dossier.

Limits on what this shows

• At-risk subgroups: Not established in humans; this is a prolonged, high-dose dietary-exposure mouse model and has not been replicated as a serum iron/ferritin finding in tamoxifen-treated patients at standard clinical dosing.

Population evidence

Mouse model, C57BL background, 0.5 g/kg tamoxifen diet for 3 months: increased liver/body weight ratio, elevated ALT/AST, elevated lipid-peroxidation markers (MDA, LPO), elevated ferroptosis markers (COX-2, GPX4, SLC7A11, ACSL4), upregulated iron transporters (STEAP3, DMT1), increased hepatic iron deposition, and altered hepcidin regulation. FASEB J. 2025. PMID 39792062.

Mechanism

Named: upregulated hepatic iron importers (STEAP3, DMT1) plus disrupted hepcidin regulation driving iron accumulation, which in turn drives lipid peroxidation and ferroptotic hepatocyte injury.

Related evidence

A separate mouse erythroid-toxicity study (see Oxygen delivery/utilization) implicates NCOA4, the ferritinophagy receptor that releases stored iron for erythropoiesis, in tamoxifen's effect on red-cell production, a mechanistically related but distinct iron-handling finding.

Overlap

Shares its source with the Oxidative stress entry's counter-evidence (same mouse livers, same paper, both iron and lipid-peroxidation endpoints); see Overlap map.

Counter-evidence held on record

This is a retention/excess-risk finding, not a deficiency. Iron supplementation should not be recommended on the basis of tamoxifen use; if anything, this animal signal argues for caution around iron supplementation in the small subset of patients who might already have elevated hepatic iron stores.

Limits on what this shows

• Key negative/null finding: Shannon diversity and overall community structure (PERMANOVA) were both non-significant; this is not a picture of global dysbiosis, only of specific taxon-level shifts.
• At-risk subgroups: Not established; the human cohort was exclusively postmenopausal ER+/HER2- patients.

Regulatory status

Not addressed in the FDA label.

Population evidence

Prospective observational study, three Dutch hospitals, 2017-2022, 62 postmenopausal ER+/HER2- breast cancer patients, 60 paired fecal samples before/during tamoxifen. ASV richness increased (P=0.019); Shannon diversity index unchanged (P=0.166); overall community structure unchanged (PERMANOVA P=0.166). Genera significantly increased: Blautia (P-adj=0.003), Streptococcus (P-adj=0.010), and others; significantly decreased: Prevotella_9 (P-adj=0.006), Subdoligranulum (P-adj=0.036). No significant correlation between microbiota composition and endoxifen plasma levels survived multiple-comparison correction. Sci Rep. 2025. PMC11885672.

Mechanism

Not established in the human cohort itself. A separate mouse mechanistic study links tamoxifen-driven gut dysbiosis to depletion of the bile acid hyodeoxycholic acid (HDCA) and disrupted Farnesoid X receptor (FXR) signaling in the gut-liver axis, contributing to hepatotoxicity; restoring HDCA or transplanting healthy microbiota reversed the liver injury in that model. Gut Microbes. 2026. PMID 41482667 (mouse).

Counter-evidence held on record

Taxon-level shifts with preserved overall diversity should not be marketed as "tamoxifen disrupts your microbiome" in the global sense; the mouse hepatotoxicity mechanism is real but has not been confirmed to operate the same way in treated patients.

Limits on what this shows

• Key negative/null finding: The same paper found a biphasic, dose-dependent pattern (mild stimulation at low concentration, inhibition/uncoupling only above a threshold), which argues against a simple "tamoxifen always impairs ATP production" framing at all exposure levels.

Population evidence

Isolated rat liver mitochondria, in vitro. Below about 40 nmol/mg protein tamoxifen stimulates basal (state 4) respiration; above that range it strongly inhibits active (state 3) respiration, reduces the respiratory control ratio and ADP/O ratio, and perturbs mitochondrial transmembrane potential. Toxicology. DOI 10.1016/S0041-008X(01)99265-8.

Mechanism

Increased inner-membrane proton permeability from structural disruption of the membrane, causing proton leak and loss of the potential gradient that drives ATP synthase; named and drug-specific, not a class extrapolation.

Overlap

Shares its evidentiary root (isolated hepatic mitochondria as the experimental model) with the Mitochondrial burden entry; see Overlap map.

Counter-evidence held on record

This is an isolated-mitochondria, dose-dependent finding, not a demonstrated clinical fatigue or ATP-deficit syndrome in patients at standard 20 mg/day dosing. No supplement (e.g., CoQ10, creatine, ribose) dose is implied by this entry.

Limits on what this shows

• Key negative/null finding: Recovery of blood counts by day 21 in the mouse model suggests a reversible, exposure-dependent effect rather than permanent marrow injury.
• At-risk subgroups: The mouse dose (200 mg/kg) is far above human therapeutic exposure (20 mg/day, roughly 0.3 mg/kg); this is a substantial, unresolved dose gap that limits direct translation to standard clinical dosing.

Regulatory status

FDA label, section 5.7 (general warnings/postmarketing): leukopenia has been observed, sometimes in association with anemia; thrombocytopenia was recorded at 2% on tamoxifen versus 1% on placebo in the NSABP B-14 adjuvant trial. FDA label / DailyMed; accessdata.fda.gov label PDF

Population evidence

Mouse study (Sv129/J background, wild-type and Ncoa4-knockout littermates), 200 mg/kg tamoxifen by oral gavage daily for 5 days: even wild-type mice showed significant reductions in red-cell count, hemoglobin and hematocrit by day 11, with recovery beginning by day 21; the effect was substantially more severe in Ncoa4-null animals. Haematologica, tamoxifen erythroid toxicity / NCOA4 study.

Mechanism

Proposed disruption of estrogen-receptor and other nuclear-receptor signaling controlling erythroid progenitor differentiation, with NCOA4 (the ferritinophagy receptor that liberates iron for erythropoiesis) implicated in the severity of the effect, linking this category to the Iron entry below.

Overlap

Shares its NCOA4/iron-handling mechanism with the Iron entry; see Overlap map.

Counter-evidence held on record

Anemia is a clinical outcome, not itself an iron or B12 deficiency; nothing here should be read as evidence that tamoxifen depletes a specific hematinic nutrient, only that erythropoiesis itself can be suppressed at high exposure.